Reported May 27, 2026 · Ongoing
Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by
Zydus Pharmaceuticals (USA) Inc.
Moderate riskThis product could cause temporary or reversible health problems — stop using it.What you should do
Stop using the affected lot and contact the recalling firm for the return or refund process. Check the FDA enforcement report for lot-level detail.
Firm contact: Zydus Pharmaceuticals (USA) Inc · 73 Route 31 N · Pennington, NJ · 08534-3601
Is this the product you have?
Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by
3 of 3 products
| # | Product as published |
|---|---|
| 1 | Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534 |
| 2 | 30 count bottles (NDC 70710-1047-3) |
| 3 | 100 count bottles (NDC 70710-1047-1). |
- Lot codes and dates
- Lotsa) M411146
- Expires
08/2026M502098M502097
- Expires
01/2027b) M411145
- Expires08/2026
- Amount recalled
- 23,880 bottles
This recall covers 2 products
The agency filed one notice per product. You are reading one of them; the other one is below.
Where it was sold
- Nationwide
Why it was recalled
CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit
This product could cause temporary or reversible health problems — stop using it.
Want the full recall guide?
The guide adds the identifying codes laid out for scanning, symptoms to watch for, a timeline, and news coverage of this recall.
Free recall alerts
Get alerted about new Zydus Pharmaceuticals (USA) Inc. recalls
One email when a matching recall is published. No account, no cost, unsubscribe in one click.
We email you about recalls and nothing else. Every send has a one-click unsubscribe, and you can change your preferences any time without an account.